Gene therapy kills breast cancer stem cells, boosts chemotherapy

Targeted agent avoids healthy cells, blocks proteins that prevent cell death in tumors

2011-09-13

(Press-News.org) HOUSTON -- Gene therapy delivered directly to a particularly stubborn type of breast cancer cell causes the cells to self-destruct, lowers chance of recurrence and helps increase the effectiveness of some types of chemotherapy, researchers at The University of Texas MD Anderson Cancer Center reported in the Sept. 13 edition of Cancer Cell.

In cellular and mouse studies, scientists found the gene mutation BikDD significantly reduced treatment-resistant breast-cancer initiating cells (BCICs), also known as breast cancer stem cells, by blocking the activity of three proteins in the Bcl-2 family. This genetic approach increased the benefits of lapatinib, one of the most common chemotherapy drugs for breast cancer.

"There are no effective methods to target BCICs, and they're urgently needed, especially for relapsed breast cancer patients," said senior author Mien-Chie Hung, Ph.D., vice president for basic research, professor and chair of MD Anderson's Department of Molecular and Cellular Oncology. "This research suggests a potential therapeutic approach to breast cancer stem cells that will minimize recurrence and drug resistance."

Special delivery system targets cells

Gene therapy was deposited directly into breast cancer cells with an innovative delivery system called VISA, short for versatile expression vector, which was developed at MD Anderson. It includes a targeting agent, also called a promoter, two components that boost gene expression in the target tissue and a payload -- a Bik mutant gene called BikDD known to kill cancer cells. It's all packaged in a fatty ball called a liposome and delivered intravenously.

This system has been successfully applied in pancreatic, lung, liver and ovarian cancer preclinical models. MD Anderson clinical researchers are preparing a phase I clinical trial for pancreatic cancer.

Stem cells frequently stymie treatment

Breast cancer stem cells, often resistant to chemotherapy and radiotherapy, are a major obstacle for breast cancer treatment, Hung said. If any of these cells remain after treatment, a new tumor often forms. Although lapatinib, known commercially as Tykerb®, can stabilize the level of these cells, no drugs are available to reduce them.

The Bcl-2 family of proteins – especially the subtypes Bcl-2, Bcl-xL and Mcl-1 -- is essential for breast cancer tumor growth and treatment resistance. If too many of these three proteins are present, they can cause poor prognosis and resistance to chemotherapy drugs including lapatinib, as well as paclitaxel, doxorubicin and cisplatin.

This study shows that Bcl-2 proteins help breast cancer stem cells survive, causing resistance to treatment and likelihood of recurrence. However, using VISA to deliver BikDD can block the three key Bcl-2 proteins, eliminating the stem cells.

VISA-claudin4-BikDD cuts tumor burden

The researchers engineered a VISA that contained claudin4, a protein over-expressed in breast cancer, as a targeting agent to preferentially express BikDD in breast cancer cells. This process silenced the three Bcl-2 proteins and caused the cancer cells to self-destruct. Since the VISA focused the BikDD on cancer cells, normal cells were not affected.

Treating mice with the VISA-claudin4-BikDD therapy reduced tumor volume by 75 percent compared to control mice.

They also compared VISA-claudin4-BikDD therapy to BikDD packaged with a non-specific strong promoter from cytomegalovirus. Both versions reduced tumor burden and extended survival of mice, but tumor volume in mice treated with VISA-claudin4-BikDD was half that of the CMV-BikDD-treated mice. In a safety study using an unusually high dose, 60 percent of mice treated with CMV-BikDD survived after three days; all mice treated with VISA-Claudin4-BikDD survived for the duration of the 14-day safety profile study.

In cell line experiments, the CMV-BikDD also invaded and destroyed normal cells, while the VISA-Claudin4-BikDD did not.

Agent energizes lapatinib, other drugs

BikDD made HER2-positive breast cancer cells more sensitive to lapatinib when all three Bcl-2 proteins were inhibited but not when they were inhibited separately. HER2-positive breast cancer is a particularly aggressive type that makes too much human epidermal growth factor 2; it accounts for about 20 percent of breast cancers. BikDD also sensitized EGFR+ (epidermal growth factor positive) breast cancer cells to lapatinib and several other breast cancer cells lines to paclitaxel.

Moving discovery forward

Hung said this approach is promising for breast cancer treatment, especially recurrent disease.

"VISA-claudin4-BikDD gene therapy may provide an effective strategy to inhibit breast tumor growth," he said. "It demonstrates virtually no toxicity in normal cells and produces a profound killing effect in multiple breast cancer cell lines and synergy with other agents."

Hung said the next step is to move VISA-claudin4-BikDD into a Phase I clinical trial to test its effect on patients with breast cancer.

### This work was supported by grants from the National Cancer Institute, including MD Anderson's Specialized Program in Research Excellence grant, the MD Anderson/China Medical University Hospital Sister Institution Fund, the Breast Cancer Research Foundation, National Breast Cancer Foundation, Inc., Patel Memorial Breast Cancer Research Fund, MD Anderson's Center for Biological Pathways and NCI Cancer Center Support Grant, and the Taiwan Department of Health Cancer Center Research of Excellence Grant.

In addition to Hung, MD Anderson researchers include first author Jing-Yu Lang, Ph.D., first author, Jennifer Hsu, Ph.D., Chun-Ju Chang, Ph.D., Qingfei Wang, Ph.D., Xiaoming Xie, Ph.D., Yi Bao, Ph.D., Hirohito Yamaguchi, Ph.D. and Dihua Yu, M.D., Ph.D., Department of Molecular and Cellular Oncology; Funda Meric-Bernstam, M.D., Department of Surgical Oncology; Wendy Woodward, M.D., Ph.D., Department of Radiation Oncology; and Gabriel Hortobagyi, M.D., Department of Breast Medical Oncology.

Hung and Hsu hold joint appointments at China Medical University and Asia University, Taichung, Taiwan. Xie holds an appointment at Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.

About MD Anderson The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For eight of the past 10 years, including 2011, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.

Get MD Anderson News Via RSS Follow MD Anderson News on Twitter

ELSE PRESS RELEASES FROM THIS DATE:

50 new exoplanets discovered by HARPS

2011-09-13

The HARPS spectrograph on the 3.6-metre telescope at ESO's La Silla Observatory in Chile is the world's most successful planet finder [1]. The HARPS team, led by Michel Mayor (University of Geneva, Switzerland), today announced the discovery of more than 50 new exoplanets orbiting nearby stars, including sixteen super-Earths [2]. This is the largest number of such planets ever announced at one time [3]. The new findings are being presented at a conference on Extreme Solar Systems where 350 exoplanet experts are meeting in Wyoming, USA. "The harvest of discoveries from ...

Stimulation of female genital regions produces strong activation of various brain sites

2011-09-13

A new study published in The Journal of Sexual Medicine reveals that for the first time, stimulation of the vagina, cervix, or clitoris was shown to activate three separate and distinct sites in the sensory cortex. Some sexuality experts have claimed that the major source of genital sensation is from the clitoris, with relatively little sensation produced by vaginal or cervical stimulation. Researchers led by Barry R. Komisaruk, B.S., Ph.D., of Rutgers University, used functional magnetic resonance imaging (fMRI) to map sensory cortical responses to clitoral, vaginal, ...

Amapola Supermarkets Celebrates 50 Years of Serving the Latino Community

2011-09-13

The celebration will take place Sept. 25, 2011, from noon to 6 p.m., at the Downey location in Downey, CA. As a thank you to its loyal customers, Amapola Supermarkets will provide food and entertainment, including famous Latino KBUE radio personality Don Cheto and Alberto Murillo. On September 22, Amapola will also host a private VIP celebration for selected guests and local dignitaries as demonstration of gratitude for their support during these past years. The festivities and awareness campaign of Amapola's 50th Anniversary is being overseen by the award-winning Los ...

Sugar-free polyol gum, lozenges, hard candy; Nonfluoride varnishes help prevent cavities

2011-09-13

CHICAGO, Sept. 12, 2011 – A multi-disciplinary expert panel, convened by the American Dental Association (ADA) Council on Scientific Affairs, issued a report this month containing clinical recommendations that sugar-free chewing gum, lozenges and hard candy including xylitol or polyol combinations, and a prescription varnish with chlorhexidine and thymol could be beneficial in preventing cavities when used as adjuncts to a comprehensive cavity prevention program which includes the use of fluoride-containing products. The panel noted in its report that these nonfluoride ...

High-fat diet and lack of enzyme can lead to heart disease in mice

2011-09-13

PHILADELPHIA - It's no secret that a high-fat diet isn't healthy. Now researchers have discovered a molecular clue as to precisely why that is. Writing in the Journal of Biological Chemistry, Mitchell Lazar, MD, PhD, the Sylvan Eisman Professor of Medicine and director of the Institute for Diabetes, Obesity, and Metabolism at the Perelman School of Medicine at the University of Pennsylvania, and colleagues, describe that mice lacking a gene-expression-controlling enzyme fed a high-fat diet experience rapid thickening of the heart muscle and heart failure. This molecular ...

Cognition research aims to reduce medical errors

2011-09-13

WASHINGTON – How doctors, nurses and other health care professionals can be better prepared to reduce medical mistakes and improve patient care is the focus of several studies published in a special issue of the American Psychological Association's Journal of Experimental Psychology: Applied. "These studies examine the cognitive issues related to a wide range of important safety problems in various health care scenarios, from hospital operating rooms to young adult education programs about sexually transmitted disease," said Daniel G. Morrow, PhD, of the University of ...

SAFEPED helps cities fix dangerous intersections

2011-09-13

Traffic planners and engineers worry about "black spots" — intersections that experience a high incidence of traffic accidents. But when it comes to designing safer roads, they lack effective tools to determine what turns a junction into a danger zone for cars and pedestrians alike. Now Ph.D. student Gennady Waizman of Tel Aviv University's Geosimulation Lab at the Department of Geography and the Human Environment and Porter School of Environmental Science has developed SAFEPED, a computer simulation that integrates robotics and statistics on driver and pedestrian behavior ...

3 in 1: team finds the gene responsible for three forms of childhood neurodegenerative diseases

2011-09-13

This press release is available in French. A Montreal-led international team has identified the mutated gene responsible for three forms of leukodystrophies, a group of childhood-onset neurodegenerative disorders. Mutations in this gene were identified in individuals from around the world but one mutation occurs more frequently in French-Canadian patients from Quebec. Published in the September issue of the American Journal of Human Genetics and selected for the Editors' Corner of the journal, the findings are crucial to the development of diagnostic tests and genetic ...

Making 1 into 2 -- first German genome comprehensively resolved at its molecular level

2011-09-13

This press release is available in German. Errors in the copying and reading of genes can have very serious consequences. Fortunately human genetic material is available in duplicate as everyone inherits a complete genome from both their mother and father. However, the two genomes are different: researchers refer to the different variants of the gene sequence on the individual chromosomes as "haplotypes" and the complete analysis of the genome requires detailed knowledge of both haplotypes. Scientists at the Max Planck Institute for Molecular Genetics in Berlin have now ...

Bands and Musicians Make An Impression and Save Money With High Quality Band and Musician Press Kits From Print It Fast Online

2011-09-13

Print It Fast Online, a leading online printing company, has recently expanded their line of printed products to include Band and Musician Press Kits. Musicians can now easily purchase all their printed press kit materials at discount prices at one online printing store. Band and Musician Press kits typically include a cover letter, artist bio, lyric sheets, set list, business card, and promotional posters or flyers along with a demo CD in a presentation folder. Print It Fast Online's discount prices on high quality printed press kits help independent artists put together ...

In small preliminary study, fearful pet dogs exhibited significantly different microbiomes and metabolic molecules to non-fearful dogs, suggesting the gut-brain axis might be involved in fear behavior

Examination of Large Language Model "red-teaming" defines it as a non-malicious team-effort activity to seek LLMs' limits and identifies 35 different techniques used to test them

Most microplastics in French bottled and tap water are smaller than 20 µm - fine enough to pass into blood and organs, but below the EU-recommended detection limit

Gene therapy kills breast cancer stem cells, boosts chemotherapy

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: